Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Renal Cell 144Carcinoma, Non-Small-Cell Lung 51Carcinoma, Transitional Cell 50Melanoma 46Urinary Bladder Neoplasms 42Prostatic Neoplasms 32Kidney Neoplasms 29Neoplasm Metastasis 27Colorectal Neoplasms 26Squamous Cell Carcinoma of Head and Neck 21Carcinoma, Hepatocellular 20Triple Negative Breast Neoplasms 15Neoplasms 15Stomach Neoplasms 14Ovarian Neoplasms 14Clear-cell metastatic renal cell carcinoma 14Lung Neoplasms 13Uterine Cervical Neoplasms 12Carcinoma, Merkel Cell 11Small Cell Lung Carcinoma 9Pancreatic Neoplasms 9Head and Neck Neoplasms 8Esophageal Neoplasms 7Breast Neoplasms 7Urethral Neoplasms 6Endometrial Neoplasms 6Cholangiocarcinoma 6Urogenital Neoplasms 5Skin Neoplasms 5Recurrence 5

Interventions

pembrolizumab 2enfortumab vedotin 2Gemcitabine 2Carboplatin 2zimberelimab 1sirtratumab vedotin 1sacituzumab govitecan 1olaparib 1avelumab 1Oxaliplatin 1Nivolumab 1Cisplatin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Metastatic Urothelial Cancer × Nivolumab × Genitourinary × Clear all
NCT03451331 2024-05-16

Gemcitabine + Carboplatin + Nivolumab Versus Gemcitabine + Oxaliplatin + Nivolumab in Cisplatin-ineligible Patients With Metastatic Urothelial Cancer

Hoosier Cancer Research Network

Phase 2 Completed
49 enrolled 15 charts
Genitourinary

Metastatic Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡